Stock listing
NASDAQ:PULM Pulmatrix, Inc. Stock
Home listing (NASDAQ) of Pulmatrix, Inc.
Follow Pulmatrix, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PULM
$1.27 USD -0.07 (-5.2%)
Close on Nov 20, 2026
- Day range
- $1.20 – $1.42 USDNov 20, 2026
- Volume
- 90,740 sharesNov 20, 2026
- Market cap
- $4.64M USDAt the close on Nov 20, 2026 · price × 3.65M shares outstanding
- 52-week range
- $1.06 – $4.94 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $49,786 USDMedian day 14,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PULM · Home | $1.27 USD | -0.07 (-5.2%) | 90,740 | $1.39 | $1.424 | $1.20 | $1.34 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PULM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.27 | -0.07 | -5.2% | $1.39 | $1.424 | $1.20 | 90,740 | |
| $1.34 | -0.03 | -2.2% | $1.32 | $1.36 | $1.30 | 5,883 | |
| $1.37 | +0.04 | +3.0% | $1.325 | $1.37 | $1.325 | 3,529 | |
| $1.33 | +0.04 | +3.1% | $1.29 | $1.389 | $1.25 | 18,361 | |
| $1.29 | -0.01 | -0.8% | $1.27 | $1.30 | $1.25 | 5,502 | |
| $1.30 | -0.01 | -0.8% | $1.34 | $1.34 | $1.22 | 9,771 | |
| $1.31 | -0.04 | -3.0% | $1.33 | $1.365 | $1.291 | 4,122 | |
| $1.35 | -0.005 | -0.4% | $1.30 | $1.42 | $1.30 | 9,396 | |
| $1.355 | -0.025 | -1.8% | $1.38 | $1.46 | $1.28 | 21,256 | |
| $1.38 | -0.02 | -1.4% | $1.37 | $1.445 | $1.32 | 9,987 | |
| $1.40 | -0.12 | -7.9% | $1.52 | $1.52 | $1.36 | 114,039 | |
| $1.52 | +0.19 | +14.3% | $1.29 | $1.54 | $1.06 | 218,269 | |
| $1.33 | -0.07 | -5.0% | $1.32 | $1.47 | $1.30 | 55,934 | |
| $1.40 | 0.00 | 0.0% | $1.365 | $1.40 | $1.335 | 5,486 | |
| $1.40 | -0.015 | -1.1% | $1.41 | $1.45 | $1.35 | 9,193 | |
| $1.415 | -0.085 | -5.7% | $1.46 | $1.475 | $1.31 | 5,735 | |
| $1.50 | +0.01 | +0.7% | $1.47 | $1.535 | $1.43 | 8,245 | |
| $1.49 | +0.05 | +3.5% | $1.52 | $1.56 | $1.42 | 68,370 | |
| $1.44 | -0.04 | -2.7% | $1.45 | $1.48 | $1.39 | 6,397 | |
| $1.48 | +0.06 | +4.2% | $1.40 | $1.483 | $1.40 | 9,000 | |
| $1.42 | -0.15 | -9.6% | $1.49 | $1.52 | $1.40 | 27,700 | |
| $1.57 | +0.14 | +9.8% | $1.40 | $1.61 | $1.376 | 130,700 | |
| $1.43 | +0.01 | +0.7% | $1.40 | $1.44 | $1.39 | 13,900 | |
| $1.42 | +0.06 | +4.4% | $1.35 | $1.46 | $1.35 | 37,200 | |
| $1.36 | -0.05 | -3.5% | $1.42 | $1.475 | $1.35 | 15,000 | |
| $1.41 | +0.04 | +2.9% | $1.36 | $1.485 | $1.34 | 22,100 | |
| $1.37 | -0.01 | -0.7% | $1.36 | $1.39 | $1.35 | 10,000 | |
| $1.38 | -0.05 | -3.5% | $1.40 | $1.42 | $1.36 | 32,800 | |
| $1.43 | -0.03 | -2.1% | $1.465 | $1.509 | $1.42 | 8,600 | |
| $1.46 | -0.067 | -4.4% | $1.47 | $1.48 | $1.43 | 4,400 | |
| $1.527 | +0.037 | +2.5% | $1.45 | $1.58 | $1.42 | 13,100 | |
| $1.49 | +0.06 | +4.2% | $1.46 | $1.51 | $1.43 | 11,900 | |
| $1.43 | -0.05 | -3.4% | $1.50 | $1.58 | $1.41 | 19,500 | |
| $1.48 | -0.09 | -5.7% | $1.55 | $1.59 | $1.451 | 24,100 | |
| $1.57 | +0.03 | +1.9% | $1.59 | $1.599 | $1.48 | 15,300 | |
| $1.54 | +0.02 | +1.3% | $1.54 | $1.55 | $1.497 | 7,900 | |
| $1.52 | -0.037 | -2.4% | $1.54 | $1.58 | $1.50 | 8,400 | |
| $1.557 | -0.033 | -2.1% | $1.59 | $1.63 | $1.555 | 7,400 | |
| $1.59 | -0.02 | -1.2% | $1.68 | $1.68 | $1.543 | 40,100 | |
| $1.61 | -0.06 | -3.6% | $1.64 | $1.697 | $1.60 | 11,900 | |
| $1.67 | -0.015 | -0.9% | $1.685 | $1.72 | $1.66 | 14,300 | |
| $1.685 | -0.015 | -0.9% | $1.72 | $1.755 | $1.65 | 29,500 | |
| $1.70 | +0.02 | +1.2% | $1.77 | $1.776 | $1.645 | 113,000 | |
| $1.68 | +0.24 | +16.7% | $1.39 | $1.68 | $1.39 | 249,500 | |
| $1.44 | +0.007 | +0.5% | $1.40 | $1.46 | $1.38 | 23,000 | |
| $1.433 | +0.033 | +2.4% | $1.40 | $1.433 | $1.38 | 14,200 | |
| $1.40 | -0.045 | -3.1% | $1.44 | $1.44 | $1.382 | 17,100 | |
| $1.445 | -0.005 | -0.3% | $1.425 | $1.445 | $1.41 | 3,400 | |
| $1.45 | +0.04 | +2.8% | $1.39 | $1.47 | $1.39 | 7,500 | |
| $1.41 | -0.05 | -3.4% | $1.44 | $1.46 | $1.41 | 7,300 | |
| $1.46 | -0.02 | -1.4% | $1.51 | $1.51 | $1.40 | 24,500 | |
| $1.48 | +0.085 | +6.1% | $1.49 | $1.66 | $1.43 | 328,400 | |
| $1.395 | +0.005 | +0.4% | $1.38 | $1.412 | $1.36 | 7,400 | |
| $1.39 | +0.03 | +2.2% | $1.36 | $1.45 | $1.36 | 20,200 | |
| $1.36 | -0.11 | -7.5% | $1.44 | $1.46 | $1.36 | 20,300 | |
| $1.47 | -0.055 | -3.6% | $1.59 | $1.59 | $1.43 | 18,400 | |
| $1.525 | +0.055 | +3.7% | $1.525 | $1.525 | $1.525 | 900 | |
| $1.47 | -0.04 | -2.6% | $1.45 | $1.485 | $1.45 | 2,600 | |
| $1.51 | -0.01 | -0.7% | $1.49 | $1.52 | $1.458 | 3,300 | |
| $1.52 | -0.005 | -0.3% | $1.50 | $1.60 | $1.467 | 14,000 | |
| $1.525 | -0.075 | -4.7% | $1.56 | $1.56 | $1.525 | 5,300 | |
| $1.60 | +0.05 | +3.2% | $1.49 | $1.60 | $1.49 | 12,200 | |
| $1.55 | +0.055 | +3.7% | $1.43 | $1.58 | $1.43 | 16,800 | |
| $1.495 | -0.005 | -0.3% | $1.50 | $1.55 | $1.49 | 39,600 | |
| $1.50 | -0.02 | -1.3% | $1.50 | $1.56 | $1.50 | 22,200 |
Splits
3 splits since 2015 · NASDAQ:PULM · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation | |
| 1-for-10 | Consolidation | |
| 2-for-5 | Consolidation |
- Ticker
- NASDAQ:PULM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger
Latest deck · Oct 22, 2026
Merger or Acquisition (October 2026)
Merger or acquisition · 35 slides
Latest news
Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger
Nov 17, 2026
Closed $1.37 (+3.0%) on Nov 17, 2026
Eos SENOLYTIX’s PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference
Nov 9, 2026
Closed $1.36 (-1.8%) on Nov 9, 2026
Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
Oct 30, 2026
Closed $1.40 (-1.1%) on Oct 30, 2026
Issued by another party
Eos SENOLYTIX Presents Late-Life Survival and Healthspan Data for Mitochondria-Targeted Geropeptide PTC-2105 at the 17th World Congress on Targeting Mitochondria, and Launches “Team Speedy” to Let the Public Follow Its Longest-Lived Mouse
Oct 22, 2026
Closed $1.42 (-9.6%) on Oct 22, 2026
Issued by another party
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Aug 13, 2026
Closed $1.51 (-5.6%) on Aug 13, 2026
Pulmatrix Announces First Quarter 2026 Financial Results
May 15, 2026
Closed $1.25 (-1.6%) on May 15, 2026
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
Apr 21, 2026
Closed $1.38 (+2.6%) on Apr 21, 2026
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Mar 26, 2026
Closed $1.51 (-28.8%) on Mar 26, 2026
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Mar 2, 2026
Closed $1.89 (-36.8%) on Mar 2, 2026
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
Feb 26, 2026
Closed $2.91 (-9.3%) on Feb 26, 2026
Pulmatrix, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 11 in the last 12 months · 89 in all · newest Nov 17, 2026 · oldest 2019
- Decks
- 38 decks · latest Oct 22, 2026
Where Pulmatrix, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PULM · Home listing · This page | NASDAQ | United States | USD |
| LS Exchange:A3DWEE | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3DWEE | Lang & Schwarz | Germany | EUR |
| BOATS:PULM | BOATS | United States | USD |
| Frankfurt:2PU | Frankfurt | Germany | EUR |
| gettex:2PU | gettex | Germany | EUR |
| Dusseldorf:2PU | Dusseldorf | Germany | EUR |
| Munich:2PU | Munich | Germany | EUR |
| Stuttgart:2PU | Stuttgart | Germany | EUR |
| Tradegate:2PU | Tradegate | Germany | EUR |
Valuation
Price/book 3.5× against a median of 1.2×: 7th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $3.24M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 3.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.33
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Pulmatrix, Inc. · NASDAQ:PULM | US$4.64M | US$3.24M | n/a | n/a | n/a | 3.5× | n/a | 0.0× | 0.33 |
| Oncodesign Precision Medicine S.A. · EURONEXT:ALOPM | US$5.04M | US$8.61M | 0.8× | 30.0× | 0.9× | 1.2× | n/a | 1.6× | n/a |
| Patrys Limited · ASX:PAB | US$4.96M | US$4.47M | n/a | 8.2× | n/a | 10.2× | −363.7% | 0.0× | n/a |
| Invex Therapeutics Ltd. · ASX:IXC | US$4.86M | US$2.20M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Can-Fite BioPharma Ltd. · TASE:CANF | US$4.86M | −US$2.14M | n/a | −5.3× | n/a | 1.0× | n/a | 0.0× | n/a |
| Zenith Capital Corporation · OTC:ZHCLF | US$4.83M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.06 |
| NFL Biosciences SA · EURONEXT:ALNFL | US$4.71M | US$5.36M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TheraCryf PLC · LSE:TCF | US$4.64M | US$2.63M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| AIM ImmunoTech Inc. · AMEX:AIM | US$4.57M | −US$937,186 | n/a | −10.3× | n/a | 0.7× | n/a | 0.2× | 0.66 |
| Tissue Repair Ltd · ASX:TRP | US$4.40M | US$1.24M | n/a | 3.4× | n/a | 0.8× | −958.0% | 0.0× | n/a |
| Processa Pharmaceuticals, Inc. · NASDAQ:PCSA | US$4.37M | −US$175.8M | n/a | n/a | n/a | n/a | n/a | n/a | 1.60 |
| Median of the others | US$4.77M | US$2.20M | 0.8× | 3.4× | 0.9× | 1.2× | −660.9% | 0.0× | 0.66 |
Team and board
Officers
| Officer | Role |
|---|---|
| Peter Ludlum | Interim Chief Executive Officer |
| Rick Batycky | Chief Executive Officer |
| Todd Bazemore | Chief Operating Officer |
| Chris Cabell MD | Senior Vice President, Head of Clinical Development |
Board
| Director | Role |
|---|---|
| Michael J. Higgins | Chairman of the PULMATRiX Board of Directors |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 17, 2026 | +0.8% |
| Q2 2026 | Aug 13, 2026 | −3.8% |
| Q1 2026 | May 19, 2026 | +0.8% |
| Q4 2025 | Feb 26, 2026 | −6.8% |
| Q3 2025 | Oct 16, 2025 | +1.2% |
| Q2 2025 | Aug 6, 2025 | −6.0% |
| Q1 2025 | May 15, 2025 | +5.9% |
| Q4 2024 | Mar 26, 2025 · Before open | −2.2% |
| Q3 2024 | Nov 7, 2024 · Before open | −2.4% |
| Q2 2024 | Aug 13, 2024 · Before open | +4.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 10, 2024 · Before open | −3.3% |
| Q4 2023 | Mar 28, 2024 · Before open | +8.0% |
| Q3 2023 | Nov 9, 2023 · Before open | −3.6% |
| Q2 2023 | Aug 10, 2023 · Before open | +0.4% |
| Q1 2023 | May 12, 2023 · Before open | −4.8% |
| Q4 2022 | Mar 30, 2023 · Before open | −0.8% |
| Q3 2022 | Nov 10, 2022 · Before open | +3.1% |
| Q2 2022 | Aug 10, 2022 · Before open | +5.3% |
| Q1 2022 | May 12, 2022 · Before open | +0.8% |
| Q4 2021 | Mar 29, 2022 · Before open | +2.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (October 2026) | Merger or acquisition | 35 slides | Oct 22, 2026 |
| Merger or Acquisition (November 2024) | Merger or acquisition | 33 slides | Nov 13, 2024 |
| Investor Presentation (March 2024) | Investor deck | 32 slides | March 2024 |
| Investor Presentation (January 2024) | Investor deck | 30 slides | Jan 8, 2024 |
| Investor Presentation (July 2023) | Investor deck | 37 slides | Jul 11, 2023 |
| Corporate Update (February 2023) | Corporate update | 42 slides | Feb 3, 2023 |
| Investor Presentation (January 2023) | Investor deck | 36 slides | Jan 11, 2023 |
| Corporate Update (November 2022) | Corporate update | 31 slides | Nov 14, 2022 |
| Investor Presentation (July 2022) | Investor deck | 13 slides | Jul 12, 2022 |
| Investor Presentation (May 2022) | Investor deck | 32 slides | May 12, 2022 |
All 38 decks
Financings
| Raise | Date |
|---|---|
| Private placement of series B Convertible Preferred Stock Closed: US$1M raised · US$2.2 a share Buyers: affiliate of Eos SENOLYTIX, Inc. Use of proceeds: Working capital and other general corporate purposes | Apr 21, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Ruthigen, Inc. Priced at US$7.25 a unit on Mar 21, 2014.
- Price
- US$7.25 a unit
- Units offered
- 2,650,000 units
- Offering size
- US$19.2 million
- Underwriters' option
- Up to 397,500 more units
- Underwriter
- Dawson James Securities, Inc.
- Units delivered
- On or about Mar 26, 2014
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 24, 2013 |
| Filed publicly | Aug 8, 2013 |
| Amended 6 times | Newest Mar 12, 2014 |
| Shares registered with an exchange | Nov 13, 2013 |
| Declared effective by the SEC | Mar 21, 2014 |
| Final prospectus, with the price | Mar 21, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B3 · Prospectus | Mar 31, 2014 |
| EFFECT · Notice that a registration is effective | Mar 21, 2014 |
| 424B4 · Prospectus | Mar 21, 2014 |
| CORRESP · Letter to the SEC | Mar 20, 2014 |
| CORRESP · Letter to the SEC | Mar 14, 2014 |
| FWP · Free writing prospectus | Mar 13, 2014 |
| S-1/A · Registration statement, amended | Mar 12, 2014 |
| FWP · Free writing prospectus | Mar 11, 2014 |
| S-1/A · Registration statement, amended | Mar 11, 2014 |
| CORRESP · Letter to the SEC | Mar 10, 2014 |
All 26 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Mar 6, 2014 |
| S-1/A · Registration statement, amended | Feb 24, 2014 |
| CERTNAS · Nasdaq's certificate of listing | Nov 19, 2013 |
| CORRESP · Letter to the SEC | Nov 18, 2013 |
| CORRESP · Letter to the SEC | Nov 18, 2013 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 13, 2013 |
| S-1/A · Registration statement, amended | Nov 7, 2013 |
| FWP · Free writing prospectus | Nov 1, 2013 |
| S-1/A · Registration statement, amended | Oct 31, 2013 |
| S-1/A · Registration statement, amended | Oct 16, 2013 |
| CORRESP · Letter to the SEC | Oct 15, 2013 |
| UPLOAD · Letter from the SEC | Aug 23, 2013 |
| CORRESP · Letter to the SEC | Aug 8, 2013 |
| S-1 · Registration statement | Aug 8, 2013 |
| UPLOAD · Letter from the SEC | Jun 24, 2013 |
| DRS · Draft registration statement | May 24, 2013 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 21, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 7.81M | 7.30M | 6.07M | 5.17M | 12.6M | 7.91M | 153.0K | 335.0K | 835.0K |
| Cost of revenue | 38.0K | 7.17M | 15.5M | 1.54M | 15.4M | 12.8M | 13.0M | 10.2M | 10.2M | |
| Gross profit | -38.0K | 640.0K | -8.22M | 6.07M | -10.2M | 12.6M | -4.93M | -12.8M | -9.91M | -9.32M |
| Research and development | 38.0K | 7.17M | 15.5M | 18.2M | 15.4M | 15.6M | 12.8M | 13.0M | 10.2M | 10.2M |
| Selling, general and administrative | 5.13M | 7.79M | 6.52M | 6.78M | 6.38M | 6.89M | 8.49M | 7.52M | 7.57M | 8.02M |
| Operating income | -5.17M | -9.76M | -14.7M | -18.9M | -20.2M | -9.86M | -20.7M | -20.4M | -17.5M | -24.9M |
| Depreciation and amortization | 0 | 106.0K | 134.0K | 162.0K | 169.0K | 215.0K | 182.0K | 231.0K | 246.0K | 250.0K |
| EBITDA | -5.17M | -9.66M | -14.6M | -18.8M | -20.0M | -9.65M | -20.5M | -20.2M | -17.2M | -24.6M |
| Interest expense | 111.0K | 4.00K | 0 | 186.0K | 186.0K | 643.0K | 881.0K | |||
| Income before tax | -5.16M | -9.56M | -14.1M | -18.8M | -20.2M | -19.3M | -20.6M | -20.6M | -18.1M | -30.8M |
| Income tax | 0 | -9.56M | 1.31M | -111.0K | 2.33M | 9.21M | 68.0K | 68.0K | -62.0K | -2.96M |
| Net income | -5.16M | -9.56M | -14.1M | -18.8M | -20.2M | -19.3M | -20.6M | -20.6M | -18.1M | -27.8M |
| Earnings per share, basic | -1.41 | -2.62 | -3.87 | -5.46 | -8.63 | -13.43 | -1.23 | -4.98 | -9.32 | -1.88 |
| Earnings per share, diluted | -1.41 | -2.62 | -3.87 | -5.46 | -8.63 | -13.43 | -1.23 | -4.98 | -9.32 | -1.88 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.09M | 9.52M | 19.2M | 35.6M | 53.8M | 31.7M | 23.4M | 2.56M | 3.55M | 4.18M |
| Short-term investments | 0 | 0 | ||||||||
| Receivables | 0 | 928.0K | 1.30M | 67.0K | 84.0K | 7.20M | 0 | 1.00K | 206.0K | |
| Inventory | -370.0K | 153.0K | 1 | 667.0K | 556.0K | 0 | 0 | |||
| Current assets | 4.13M | 9.92M | 20.8M | 38.1M | 54.8M | 32.5M | 31.4M | 3.28M | 4.25M | 4.76M |
| Property, plant and equipment | 1.16M | 235.0K | 321.0K | 361.0K | 270.0K | 394.0K | 614.0K | 786.0K | ||
| Goodwill | 0 | 3.58M | 3.58M | 10.8M | 10.9M | 10.9M | ||||
| Total assets | 4.14M | 9.94M | 34.0M | 41.0M | 58.8M | 38.1M | 36.1M | 14.7M | 16.0M | 16.7M |
| Accounts payable | 272.0K | 809.0K | 1.92M | 1.19M | 839.0K | 851.0K | 600.0K | 1.18M | 457.0K | 747.0K |
| Current liabilities | 329.0K | 929.0K | 3.91M | 5.02M | 4.44M | 8.18M | 17.2M | 2.88M | 5.84M | 4.65M |
| Long-term debt | 0 | 3.22M | ||||||||
| Total debt | 8.76M | 857.0K | 2.29M | 1.74M | 675.0K | 0 | 3.22M | 5.80M | ||
| Total liabilities | 329.0K | 996.0K | 16.0M | 9.84M | 11.4M | 15.0M | 25.1M | 2.88M | 5.84M | 7.90M |
| Shareholders' equity | 3.81M | 8.95M | 18.0M | 31.1M | 47.4M | 23.1M | 11.0M | 11.8M | 10.1M | 8.76M |
| Shares outstanding | 3.65M | 3.65M | 3.65M | 3.64M | 3.22M | 1.81M | 20.0M | 4.92M | 2.10M | 14.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -5.43M | -10.7M | -16.0M | -19.4M | -19.7M | -12.5M | 3.23M | -16.8M | -14.5M | -13.2M |
| Capital spending | 0 | -398.0K | -676.0K | -86.0K | -144.0K | -281.0K | -58.0K | -19.0K | -74.0K | -455.0K |
| Free cash flow | -5.43M | -11.1M | -16.7M | -19.4M | -19.9M | -12.8M | 3.17M | -16.8M | -14.6M | -13.7M |
| Cash from investing | -398.0K | -676.0K | -86.0K | -144.0K | -281.0K | -58.0K | -19.0K | -74.0K | -431.0K | |
| Cash from financing | 0 | 53.0K | 1.23M | 43.5M | 21.0M | 17.7M | 15.8M | 13.9M | -1.05M | |
| Dividends paid | -3.20M | 0 | 0 | |||||||
| Share buybacks | -152.0K | 21.0M | 17.7M | 19.3M | 16.6M | 0 | ||||
| Change in cash | -5.43M | -11.1M | -16.6M | -18.2M | 23.6M | 8.22M | 20.9M | -987.0K | -632.0K | -14.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 17, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 425 | Nov 9, 2026 | Other filings | SEC |
| 425 | Oct 30, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 27, 2026 | Meeting outcome | SEC |
| 424B3 · Prospectus | Oct 26, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 23, 2026 | Other filings | SEC |
| 425 | Oct 22, 2026 | Other filings | SEC |
| 425 | Oct 13, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Oct 7, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| DEFA14A · Additional proxy material | Oct 7, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Oct 5, 2026 | Annual report | SEC |
| S-3/A · Registration statement, amended | Oct 2, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 28, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Sep 25, 2026 | Offer document | SEC |
| DEFM14A | Sep 25, 2026 | Meeting notice | SEC |
| S-4/A · Registration statement, amended | Sep 23, 2026 | Offer document | SEC |
| 425 | Sep 22, 2026 | Other filings | SEC |
| S-4/A · Registration statement, amended | Sep 17, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Sep 4, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| S-3/A · Registration statement, amended | Aug 7, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Aug 3, 2026 | Offer document | SEC |
| S-4 · Registration statement | Jul 9, 2026 | Offer document | SEC |
| 10-K/A · Annual report, amended | Jun 16, 2026 | Annual report | SEC |
| 425 | Jun 5, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jun 4, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2026 | Results | SEC |
| DRS · Draft registration statement | May 14, 2026 | Offer document | SEC |
| SCHEDULE 13D · Big-stake notice | Apr 22, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 21, 2026 | Current report | SEC |
| D | Apr 15, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 27, 2026 | Material contract | SEC |
| 425 | Mar 26, 2026 | Other filings | SEC |
| 8-K · Current report | Mar 2, 2026 | Current report | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 8-K · Current report | Dec 18, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Oct 16, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 16, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 425 | Jun 16, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 16, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Acquisition or disposal | SEC |
| EFFECT · Notice that a registration is effective | May 12, 2025 | Other filings | SEC |
| 424B3 · Prospectus | May 9, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 8, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 7, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | May 6, 2025 | Offer document | SEC |
| S-4/A · Registration statement, amended | Apr 17, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 17, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 10, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 8, 2025 | Meeting outcome | SEC |
| 10-K · Annual report | Mar 21, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2025 | Results | SEC |
| UPLOAD · Letter from the SEC | Mar 17, 2025 | Other filings | SEC |
| S-4 · Registration statement | Feb 14, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 14, 2025 | Current report | SEC |
| 425 | Jan 22, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 20, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Nov 13, 2024 | Material contract | SEC |
| ARS · Annual report to shareholders | Nov 8, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 8, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2024 | Results | SEC |
| 8-K · Current report | Oct 8, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 8-K · Current report | Jul 19, 2024 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | May 31, 2024 | Other filings | SEC |
| 8-K · Current report | May 29, 2024 | Material contract | SEC |
| CORRESP · Letter to the SEC | May 28, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 23, 2024 | Other filings | SEC |
| S-3 · Registration statement | May 17, 2024 | Offer document | SEC |
| 8-K · Current report | May 15, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 10, 2024 | Results | SEC |
| 424B3 · Prospectus | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| 8-K · Current report | Mar 13, 2024 | Management or board change | SEC |
| 8-K · Current report | Mar 4, 2024 | Current report | SEC |
| 8-K · Current report | Jan 8, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 2, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 8-K · Current report | Jul 13, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Jul 11, 2023 | Current report | SEC |
| ARS · Annual report to shareholders | Jun 2, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Jun 2, 2023 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2023 | Results | SEC |
| 10-K · Annual report | Mar 30, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2023 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 8, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Feb 6, 2023 | Current report | SEC |
| 8-K · Current report | Feb 3, 2023 | Current report | SEC |
| 4 · Change in ownership | Jan 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 25, 2023 | Current report | SEC |
| 8-K · Current report | Jan 11, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 10, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 4, 2023 | Current report | SEC |
| 8-K · Current report | Nov 14, 2022 | Results | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| 8-K · Current report | Sep 26, 2022 | Current report | SEC |
| 10-Q · Quarterly report | Aug 10, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2022 | Results | SEC |
| 424B3 · Prospectus | Aug 9, 2022 | Offer document | SEC |
| 8-K · Current report | Jul 12, 2022 | Current report | SEC |
| 8-K · Current report | Jun 15, 2022 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 12, 2022 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2022 | Results | SEC |
| DEFA14A · Additional proxy material | May 2, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2022 | Meeting notice | SEC |
| 8-K · Current report | Apr 29, 2022 | Current report | SEC |
| 3 · Initial statement of ownership | Apr 19, 2022 | Insider trade | SEC |
| 8-K · Current report | Apr 15, 2022 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 29, 2022 | Offer document | SEC |
| 10-K · Annual report | Mar 29, 2022 | Annual report | SEC |
| 8-K · Current report | Mar 29, 2022 | Results | SEC |
| 8-K · Current report | Mar 21, 2022 | Current report | SEC |
| 8-K · Current report | Mar 17, 2022 | Current report | SEC |
| 8-K · Current report | Mar 4, 2022 | Current report | SEC |
| 4 · Change in ownership | Mar 3, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 3, 2022 | Insider trade | SEC |
| 8-K · Current report | Feb 24, 2022 | Current report | SEC |
| 8-K · Current report | Feb 15, 2022 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Feb 11, 2022 | Meeting outcome | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 11, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2022 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Feb 1, 2022 | Meeting notice | SEC |
| 4 · Change in ownership | Jan 31, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2022 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 5, 2022 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Dec 30, 2021 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Dec 30, 2021 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 20, 2021 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Dec 17, 2021 | Meeting notice | SEC |
| 8-K · Current report | Dec 17, 2021 | Current report | SEC |
| 424B5 · Prospectus | Dec 17, 2021 | Offer document | SEC |
| DEFA14A · Additional proxy material | Dec 17, 2021 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Dec 17, 2021 | Material contract | SEC |
| DEFA14A · Additional proxy material | Dec 15, 2021 | Meeting notice | SEC |
| 8-K · Current report | Dec 15, 2021 | Material contract | SEC |
| 8-K · Current report | Dec 7, 2021 | Current report | SEC |
| 10-Q · Quarterly report | Nov 10, 2021 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2021 | Results | SEC |
| 8-K · Current report | Nov 9, 2021 | Material contract | SEC |
| 8-K · Current report | Aug 23, 2021 | Current report | SEC |
| 10-Q · Quarterly report | Aug 10, 2021 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2021 | Results | SEC |
| 4 · Change in ownership | Jul 28, 2021 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 28, 2021 | Insider trade | SEC |
| 8-K · Current report | Jul 27, 2021 | Management or board change | SEC |
| D | Jul 20, 2021 | Other filings | SEC |
| 8-K · Current report | Jun 17, 2021 | Meeting outcome | SEC |
| 8-K · Current report | Jun 16, 2021 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 10, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 7, 2021 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 7, 2021 | Other filings | SEC |
| S-3 · Registration statement | May 26, 2021 | Offer document | SEC |
| 10-K/A · Annual report, amended | May 14, 2021 | Annual report | SEC |
| 8-K · Current report | May 13, 2021 | Current report | SEC |
| 10-Q · Quarterly report | May 11, 2021 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2021 | Results | SEC |
| 8-K · Current report | May 10, 2021 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2021 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2021 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Apr 13, 2021 | Current report | SEC |
| 8-K · Current report | Apr 12, 2021 | Current report | SEC |
| 8-K · Current report | Apr 5, 2021 | Management or board change | SEC |
| 10-K/A · Annual report, amended | Mar 26, 2021 | Annual report | SEC |
| 10-K · Annual report | Mar 23, 2021 | Annual report | SEC |
| 8-K · Current report | Mar 23, 2021 | Results | SEC |
| 8-K · Current report | Mar 4, 2021 | Current report | SEC |
| SC 13D · Big-stake notice | Feb 25, 2021 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 24, 2021 | Big-stake notice | SEC |
| D | Feb 23, 2021 | Other filings | SEC |
| 8-K · Current report | Feb 16, 2021 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 16, 2021 | Big-stake notice | SEC |
| 424B5 · Prospectus | Feb 16, 2021 | Offer document | SEC |
This page holds 200 of 655 filings. Open Filings
Cap table
Built by 6ix from Pulmatrix, Inc.’s releases · as of Nov 12, 2026
- Common shares
- 3,652,285
- Fully diluted
- 3,652,285
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 3,652,285 | Nov 12, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 12, 2026 | 3,652,285 |
| Sep 30, 2026 | 3,652,285 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Terrance McGuire Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Invivyd, Inc. (Director · Since at least Aug 5, 2021); Seer, Inc. (Director · Since at least Dec 3, 2020); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Nov 30, 2023 · Past); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 14, 2014 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past) | Director · Jun 15, 2015 – May 16, 2019 · Past |
| Mark Iwicki Other companies: Inhibikase Therapeutics, Inc. (Chief Executive Officer - Inhibikase · Since at least Feb 14, 2025); Q32 Bio Inc. (Director · Since at least Mar 25, 2024); Third Harmonic Bio Inc. (Director · Since at least Sep 14, 2022); Akero Therapeutics Inc (Director · Since at least Jun 19, 2019); Kala Bio, Inc. (Director · Since at least Jul 19, 2017); Jade Biosciences, Inc. (Director · Apr 2, 2021 – Jun 5, 2024 · Past); Aimmune Therapeutics Inc (Director · May 25, 2016 – Oct 10, 2020 · Past) | Director · Mar 20, 2017 – Jan 28, 2021 · Past |
| Steven Gillis Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 16, 2023 · Past); VBI Vaccines Inc. (Director · Jun 14, 2019 – Jul 27, 2023 · Past); Q32 Bio Inc. (Director · Jun 6, 2019 – Jun 14, 2023 · Past) | Director · May 16, 2019 – Aug 28, 2020 · Past |
| Scott M Rocklage Other companies: Aprea Therapeutics, Inc. (Director · Oct 2, 2019 – Jun 30, 2020 · Past); Cidara Therapeutics Inc (Director · Apr 14, 2015 – Jun 13, 2018 · Past); EPIRUS Biopharmaceuticals Inc (Director · Jul 15, 2014 – Jun 5, 2015 · Past); Achaogen Inc (Director · Mar 11, 2014 – Mar 11, 2014 · Past); Relypsa Inc (Director · Nov 14, 2013 – Nov 20, 2013 · Past) | Director · Jun 15, 2015 – Feb 3, 2016 · Past |
| Michael J. Higgins Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Oct 10, 2024); Voyager Therapeutics, Inc. (Chair · Since at least Nov 10, 2015); Cyclerion Therapeutics, Inc. (Director · Nov 30, 2023 – Mar 25, 2025 · Past); Ironwood Pharmaceuticals, Inc. (Chief Operating Officer · Feb 2, 2010 – Dec 23, 2014 · Past) | Chairman of the PULMATRiX Board of Directors · Since at least Jun 15, 2015 |
| Anand Varadan | Since at least Nov 4, 2026 |
| Chris Cabell MD | Senior Vice President, Head of Clinical Development · Since at least Nov 4, 2026 |
| Margaret Wasilewski | Chief Medical Officer · Mar 1, 2022 – Jan 26, 2023 · Past |
| Michelle Siegert | Vice President, Finance · Nov 13, 2019 – Jan 26, 2023 · Past |
| Peter Ludlum | Interim Chief Executive Officer · Since at least Aug 13, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Rick Batycky | Chief Executive Officer · Since at least Nov 4, 2026 |
| Sameer Harish | Chief Financial Officer · Mar 21, 2014 – May 11, 2014 · Past |
| Teofilo David Raad | Chief Executive Officer, Director · Jun 5, 2018 – Jan 26, 2023 · Past |
| Todd Bazemore | Chief Operating Officer · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Pulmatrix, Inc.